Featured Research

from universities, journals, and other organizations

Severe vasculitis: After 40 years, researchers identify possible new treatment

Date:
July 14, 2010
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
Researchers have made a major advance in treating people with a severe form of vasculitis, anti-neutrophil cytoplasmic antibody-associated vasculitis, a rare but devastating disease of blood vessels. In a six-month study, a new treatment strategy provided the same benefits as the current standard of care used for more than 40 years but required less frequent treatments.

Investigators have made a major advance in treating people with a severe form of vasculitis, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a rare but devastating disease of blood vessels. In a six-month study, a new treatment strategy provided the same benefits as the current standard of care used for more than 40 years but required less frequent treatments. Early results also suggest that patients with disease relapses -- typically recurrences of fever, fatigue, kidney damage, or bleeding in the lungs -- respond better to the new regimen.

Related Articles


The study, which appears online in the New England Journal of Medicine, was led by John Stone, M.D., M.P.H., of Massachusetts General Hospital, Boston, and Ulrich Specks, M.D., of the Mayo Clinic, Rochester, Minn. It was conducted by the Immune Tolerance Network (ITN). The ITN is an international consortium supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Juvenile Diabetes Research Foundation International. Genentech Inc., of South San Francisco, Calif., and Biogen Idec Inc., of Weston, Mass., provided additional funding for the study.

Patients with ANCA-associated vasculitis make antibodies that attack immune cells called neutrophils, causing inflammation in small- to medium-sized blood vessels. This leads to organ damage, particularly in the airways, lungs and kidneys.

There are two main forms of this type of autoimmune vasculitis -- microscopic polyangitis and Wegener's granulomatosis. These are rare, so-called orphan, diseases with approximately 6,000 newly diagnosed cases in the United States each year.

The current standard of care for ANCA-associated vasculitis combines a 3- to 6-month course of daily cyclophosphamide plus steroids, followed by long-term daily azathioprine (AZA) plus steroids. This regimen was originally developed by NIAID Director Anthony S. Fauci, M.D., and his colleagues in the early 1970s. Before this treatment regimen became available, about 80 percent of people died within two years of disease onset from kidney failure or bleeding in the lungs. The nearly 40-year-old therapy has been lifesaving for many patients.

"More than 90 percent of individuals with this once-devastating disease experience remission after they receive cyclophosphamide-based therapy," says Dr. Fauci. "Despite these gratifying results, there remains a high rate of relapse and a need for retreatment. Identifying more effective treatment options would be a welcome development."

Dr. Fauci's earlier research had shown that cyclophosphamide worked by suppressing the function of B cells, an immune cell that produces the self-destructive antibodies. However, long-term, repeated use of cyclophosphamide puts patients at increased risk of infection, cancer and infertility as well as other side effects.

In search of an alternative therapy for patients with ANCA-associated vasculitis, ITN investigators turned to rituximab, a synthetic antibody that selectively reduces the number of B cells circulating in the blood. Rituximab currently is licensed to treat some B-cell lymphomas, chronic lymphocytic leukemia and rheumatoid arthritis.

The goal of this study was twofold, says Dr. Stone. "First, we wanted to induce disease remission and reduce or eliminate maintenance steroid use. Second, we wanted to find a less toxic therapy that also will prolong remission."

In their study, the 197 participants -- 51 percent had been treated previously, 49 percent were newly diagnosed -- were divided randomly into two groups. One group received intravenous rituximab therapy once a week for one month, plus steroids. The other group received 3 to 6 months of daily cyclophosphamide therapy plus steroids, followed by daily AZA. Neither the investigators nor the patients knew the treatment assignments. After a 6-month treatment period, the investigators found that 64 percent of participants in the rituximab group and 53 percent in the cyclophosphamide group had no disease activity and were able to completely discontinue the use of steroids. According to the ITN investigators, the study has successfully demonstrated that rituximab provided comparable benefits as standard therapy for ANCA-associated vasculitis.

Moreover, in patients with relapsing disease, the new treatment worked even better. The investigators found that 67 percent of participants with relapsing disease in the rituximab group had no disease activity and were able to discontinue all steroid use after therapy, compared with only 42 percent in the cyclophosphamide group.

"Although the two therapy regimens were equally effective in reducing patients' disease activity overall, our results indicate that rituximab is superior to cyclophosphamide in inducing remission for patients experiencing a disease flare," comments Dr. Specks.

The observation that rituximab offers similar benefits for patients with ANCA-associated vasculitis, while using a much shorter treatment regimen, is a major treatment advance, according to the investigators. Significantly, they also observed no major differences in the overall side effects in patients from the two treatment groups.

According to Drs. Stone and Specks, the ITN team plans to follow the participants until 18 months after treatment to determine if patients who received rituximab relapse and to evaluate the long-term safety of this regimen.

"The goal of the ITN is to develop tolerance-inducing therapies and bring them into clinical practice for immune-mediated diseases," says Daniel Rotrosen, M.D., director of NIAID's Division of Allergy, Immunology and Transplantation. "The results show that rituximab is a valid and long-awaited alternative to cyclophosphamide therapy. We eagerly await the results from the longer term study."

Additional NIH support for this research was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Center for Research Resources' Clinical and Translational Science Awards.

For more information on Wegener's granulomatosis, visit the NIAID Wegener's granulomatosis Web portal at http://www.niaid.nih.gov/topics/wegeners/Pages/Default.aspx. Information on vasculitis can be found on the NIH Vasculitis Clinical Research Consortium website at http://rarediseasesnetwork.epi.usf.edu/vcrc/.


Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "Severe vasculitis: After 40 years, researchers identify possible new treatment." ScienceDaily. ScienceDaily, 14 July 2010. <www.sciencedaily.com/releases/2010/07/100714190136.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2010, July 14). Severe vasculitis: After 40 years, researchers identify possible new treatment. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2010/07/100714190136.htm
NIH/National Institute of Allergy and Infectious Diseases. "Severe vasculitis: After 40 years, researchers identify possible new treatment." ScienceDaily. www.sciencedaily.com/releases/2010/07/100714190136.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins